Compass Pathways has announced positive results from two Phase 3 clinical trials of its psilocybin-based drug COMP360 for the treatment of major depression.[1] In both trials, patients given this psychedelic drug showed greater improvement in depressive symptoms compared to a control group.[1] According to available data, COMP360 could be the first psilocybin product on the market and the second approved psychedelic after Johnson & Johnson's ketamine derivative Spravato.[1] Experts suggest that the data probably meet the criteria for approval, although they are not clearly spectacular.[1] The drug could represent a new approach to the treatment of depression resistant to standard pharmacological treatment, where traditional antidepressants often do not work.[7] Results from larger studies show that after a single dose of 25 mg of psilocybin combined with psychological support, 29% of patients experienced significant relief of symptoms that persisted three weeks after administration.[7]